GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Median PS Value

Innovent Biologics (HKSE:01801) Median PS Value : HK$0.00 (As of May. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Innovent Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4.345. Innovent Biologics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is HK$0.00.

As of today (2024-05-27), Innovent Biologics's share price is HK$36.15. Innovent Biologics's Median PS Value is HK$0.00. Therefore, Innovent Biologics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Innovent Biologics's Median PS Value or its related term are showing as below:

HKSE:01801's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Innovent Biologics Median PS Value Historical Data

The historical data trend for Innovent Biologics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Median PS Value Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial - - - - -

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innovent Biologics's Median PS Value

For the Biotechnology subindustry, Innovent Biologics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Price-to-Median-PS-Value falls into.



Innovent Biologics Median PS Value Calculation

Innovent Biologics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=4.345*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4.345.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics  (HKSE:01801) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Innovent Biologics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=36.15/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics Median PS Value Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Yu De-chao Michael 2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co. 2502 Approved lending agent
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Eight Roads Investments 2101 Beneficial owner
Fullerton Management Pte Ltd 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited 2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd. 2101 Beneficial owner

Innovent Biologics (HKSE:01801) Headlines

No Headlines